Foundation Medicine Announces Publication of Analytic Validation Study of FoundationOne™ in Nature Biotechnology
Publication Establishes Standard of Analytic Performance for Clinical Application of Next-Generation Sequencing in Cancer
Comprehensive genomic testing is becoming critical to deliver the most effective care for patients with cancer. However, analytic validation of NGS-based tests presents a challenge to clinical application due to the fact that thousands of potential variants may be detected, and most have no gold standard with which to compare. This publication is the first to apply and extend the guidelines established by the Next-Generation Sequencing: Standardization of Clinical Testing (Nex-StoCT) workgroup2 to validate a clinical sequencing-based assay for cancer, therefore setting the standard for validation of targeted NGS in cancer.
"Clinical cancer care is undergoing a fundamental shift toward treating patients based on the specific molecular drivers of their disease, and a sequencing-based diagnostic assay that comprehensively and accurately characterizes the genomic alterations occurring within an individual's tumor is essential for the implementation of this therapeutic strategy," stated
"FoundationOne was proven to have the sensitivity and specificity required for routine clinical practice, and it identified more than three times the clinically actionable alterations that are identifiable using a collection of six commercially available and commonly used diagnostic tests, including the other most common NGS-based tests. This comprehensive approach directly translates into more treatment options for patients," said
About
Foundation Medicine® is a registered trademark, and FoundationOneTM is a trademark of
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the shift in clinical cancer care towards precision medicine, the benefits to patients of next-generation sequencing of their tumors, and the adoption of FoundationOneTM into routine clinical oncology practice and clinical trials. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that FoundationOneTM and any subsequent products may never achieve significant commercial adoption or reimbursement support;
1. Frampton, G.M. et al. Validation and clinical application of a cancer genomic profiling test using next-generation sequencing. Nature Biotechnology, 2013; DOI: 10.1038/NBT.2696.
2. Gargis, A.S. et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nature Biotechnology 30, 1033-1036 (2012).
Media Contact:
973-271-6085
or
Investor Contact:
Source:
News Provided by Acquire Media